These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27124105)

  • 1. Concerns about idarucizumab for dabigatran reversal.
    Stöllberger C; Pommer P; Schneider B; Finsterer J
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):473-4. PubMed ID: 27124105
    [No Abstract]   [Full Text] [Related]  

  • 2. Idarucizumab for dabigatran overdose in a child.
    Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
    Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
    [No Abstract]   [Full Text] [Related]  

  • 3. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
    Jarrett JB; Gimbar RP
    Am Fam Physician; 2017 Jun; 95(12):798-800. PubMed ID: 28671421
    [No Abstract]   [Full Text] [Related]  

  • 4. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
    Finks SW; Rogers KC
    Am J Med; 2017 May; 130(5):e195-e197. PubMed ID: 28011314
    [No Abstract]   [Full Text] [Related]  

  • 5. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.
    Tomaszuk-Kazberuk A; Łopatowska P; Młodawska E; van Ryn J; Reilly PA; Pollack CV
    Pol Arch Intern Med; 2017 Jan; 127(1):68-70. PubMed ID: 28146465
    [No Abstract]   [Full Text] [Related]  

  • 9. Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran.
    Teleb M; Salire K; Wardi M; Alkhateeb H; Said S; Mukherjee D
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):25-29. PubMed ID: 27477871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).
    O'Malley PA
    Clin Nurse Spec; 2015; 29(5):262-4; quiz E8. PubMed ID: 26258832
    [No Abstract]   [Full Text] [Related]  

  • 12. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
    Miyares MA; Kuyumjian Y; Eaves S; Dollard E
    J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of Anticoagulation With Dabigatran in an 82-Year-Old Patient With Traumatic Retroperitoneal Arterial Bleeding Using the New Antidote Idarucizumab: A Case Report.
    Hofer S; Philipsenburg C; Weigand MA; Brenner T
    A A Case Rep; 2016 Dec; 7(11):227-231. PubMed ID: 27669031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Administration of idarucizumab in spontaneous intracerebral hemorrhage under dabigatran-therapy].
    Bereczki D; Szilágyi G; Kakuk I; Szakács Z; May Z
    Ideggyogy Sz; 2017 Sep; 70(9-10):349-353. PubMed ID: 29870627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal Strategies for Newer Oral Anticoagulants.
    Singer AJ; Wilson S
    AACN Adv Crit Care; 2017; 28(4):322-331. PubMed ID: 29212638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting idarucizumab for the reversal of dabigatran.
    Pollack CV
    Am J Emerg Med; 2016 Nov; 34(11S):33-38. PubMed ID: 27697436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.